PetMed Express (PETS)
(Delayed Data from NSDQ)
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
Zacks News
Integra LifeSciences (IART) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.
Booking Holdings (BKNG) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Booking Holdings' (BKNG) fourth-quarter results are driven by significant contributions from investments in people, systems and marketing.
Fitbit (FIT) Q4 Loss Greater Than Estimated, Revenues Miss
by Zacks Equity Research
Fitbit's (FIT) fourth-quarter 2017 results are impacted by weak demand for its fitness products.
NuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 View
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business in Q4.
PetMed (PET) Focuses on Advertising to Boost New Order Sales
by Zacks Equity Research
PetMed (PETS) implements several strategies to revitalize top line.
GoDaddy (GDDY) Beats Earnings & Revenue Estimates in Q4
by Zacks Equity Research
GoDaddy (GDDY) reports strong fourth-quarter revenues on the back of growth in customers, new products and contribution from HEG acquisition.
After Wayfair's Earnings Miss, Buy These E-Commerce Stocks Instead
by Ryan McQueeney
Shares of Wayfair (W) were down more than 17% in early morning trading Thursday after the e-commerce company posted a wider-than-expected fourth-quarter loss. For investors who would rather focus on e-commerce stocks that have recently posted positive earnings surprises, there are plenty of options elsewhere.
3 Retail Stocks That Crushed Earnings Estimates This Season
by Ryan McQueeney
The holiday season has the potential to make or break of retailer's fiscal year. Now that we are on the other side of the bulk of Q4's earnings announcements, we can see that several notable companies performed particularly well.
Garmin (GRMN) Q4 Earnings Beat Estimates, Issues 2018 View
by Zacks Equity Research
Garmin (GRMN) delivers strong fourth-quarter results on the back of solid performance in fitness, marine, outdoor and aviation segments.
Why Is PetMed Express (PETS) Down 9.8% Since the Last Earnings Report?
by Zacks Equity Research
PetMed Express (PETS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ecolab (ECL) Misses Q4 Earnings Estimates, View Impressive
by Zacks Equity Research
Despite strength in Global Industrial and Global Institutional segments, Ecolab (ECL) ended the fourth quarter on an unfavorable note.
Medtronic (MDT) Beats on Q3 Earnings, Reiterates FY18 View
by Zacks Equity Research
Medtronic (MDT) rides high on strength in all business segments in Q3.
The Zacks Analyst Blog Highlights: Boeing, PetMed, Micron, Healthcare and RH
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: Boeing, PetMed, Micron, Healthcare and RH
Buy These 4 Retail Growth Stocks to Brave Soft Sales Woes
by Zacks Equity Research
Looking superficially, the numbers do raise concerns but a meticulous approach may help alleviate fears. Analysts cited the slump in retail sales as a temporary hitch after a sturdy holiday season.
Inflation Scares Overblown! Grab 5 Growth Stocks Now
by Tirthankar Chakraborty
The rise in consumer price index (CPI), especially on a year-on-year basis, remained sluggish, while the recent wage growth was primarily due to seasonal factors that are not likely to last long.
TripAdvisor (TRIP) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
TripAdvisor's (TRIP) fourth-quarter results were impacted by a weak performance in the Hotel business. Also, increasing marketing investments continue to be a concern.
Applied Materials (AMAT) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Applied Materials (AMAT) delivers strong fiscal first-quarter results on the back of demand for chips used in electronic items, differentiated products, new technologies and innovation strategy.
Hone in on DuPont Analysis & Pick 5 Top Stocks
by Zacks Equity Research
Do you have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.
GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates
by Zacks Equity Research
Despite sluggish performance by manufacturing/wholesale segments, GNC Holdings (GNC) witnesses revenue growth in Q4.
DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues
by Zacks Equity Research
Impressive results from Kidney Care business drove DaVita (DVA) in Q4.
Amkor Technology (AMKR) Beats on Q4 Earnings, Revenues
by Zacks Equity Research
Amkor Technology (AMKR) delivers strong fourth-quarter earnings aided by robust growth in all end markets, primarily auto and mobile communication end markets.
Luminex (LMNX) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Luminex's (LMNX) favorable tidings at the regulatory front in Q4 buoy optimism.
Bruker (BRKR) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Bruker (BRKR) registers organic revenue growth on strength in NANO and BEST platforms in Q4.
Hologic (HOLX) Q1 Earnings & Revenues Top, Margins Down
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Molecular Diagnostics, Breast Health and international business drives the top line in Q1.